1. What are the differences between various antibody discovery platforms?

Different antibody discovery platforms vary mainly in how B cells are sourced, how antibodies are screened. Hybridoma technology uses immunized animals and fuses B cells with myeloma cells to generate stable antibody-producing clones. It is reliable and well-established but relatively time-consuming and lower throughput. Single B cell screening platforms directly isolate antigen-specific B cells and obtain paired heavy and light chain sequences. This approach is faster, higher throughput, and preserves natural antibody pairing, enabling rapid discovery of functional antibodies. Display technologies (e.g., Phage Display, yeast or mammalian display) use large in vitro libraries to screen antibodies against targets. They provide very large diversity and do not require immunization, but may require additional steps to optimize affinity and functionality.

2. How should we select the most appropriate antibody discovery platform?

Selection depends on project goals, timeline, and target characteristics. Factors to consider include: Diversity Needed (Moderate to High), Timeline (Slower to Fast), Natural Pairing (Yes or No), Species (limited to Any species), and Throughput (Low to High). Hybridoma offers natural pairing but is slower with low throughput. Single B Cell offers a fast timeline, high throughput, and natural pairing. Display technologies provide high diversity and can use any species, but lack natural pairing.

In Vivo CAR-T Hub

Explore In Vivo CAR-T Resources in One Convenient Hub White papers | Posters | Videos

Discovery

Antibody CMC

Plasmid DNA

RNA-tLNP

tLVV

Facility

Start Your In Vivo CAR-T Journey Now!

In vivo CAR-T is reshaping cell therapy by enabling direct immune cell engineering inside the patient, eliminating complex ex vivo steps such as cell extraction, modification, and reinfusion. This streamlined approach improves speed, scalability, and cost efficiency. With flexible delivery options, including RNA-LNP and viral vector technologies, in vivo CAR-T is opening a new path toward truly scalable cell therapies. This resource hub brings together expert insights, technical content, and platform capabilities to support your in vivo CAR-T journey—from discovery to delivery.

In Vivo CAR-T Discovery

Antibody CMC for In Vivo CAR-T

Plasmid DNA for In Vivo CAR-T

RNA-tLNP Delivery Pathway

Targeted Lentiviral Vector (tLVV) DeliveryPathway

Explore OurIn Vivo CAR-T Facility

In Vivo CAR-T Discovery

Build a strong foundation with optimized CAR design, antibody selection, and early-stage validation strategies.

What You’ll Learn

Strategies for CAR construct optimization
Antibody screening and lead identification
Key considerations for in vivo functionality

Learn About Our Services

Flyer

In Vivo CAR-T Discovery

Folding

Antibody Discovery for CAR-T Therapy

Webinar

Antibody Fragment CMC On-demand Webinar

Antibody CMC for In Vivo CAR-T

Ensure robust and scalable antibody fragment production with tailored CMC strategies for in vivo applications.

What You’ll Learn

Cell line development for antibody fragments
Upstream and downstream process optimization
Quality and consistency in biologics manufacturing

Learn About Our Services

Poster

Faster IND Starts with Better Cell Lines

White Paper

Addressing Upstream Challenges in

Antibody and Protein Production

Webinar

Antibody Fragment CMC On-demand Webinar

Plasmid DNA for In Vivo CAR-T

High-quality plasmid DNA is critical for both viral and non-viral delivery pathways.

What You’ll Learn

Multiple linearized DNA options
Critical quality attributes for plasmid design
Poly(A) sequence control and its impact on expression

Get Free Consultation

Flyer

Optimized Solutions for Linearized DNA

Flyer

GMP Plasmid Manufacturing

Poster

Analysis and Control of Poly(A) in

mRNA Plasmid

Webinar

Development and Manufacturing Strategy for mRNA Template Plasmids

RNA-tLNP Delivery Pathway

Enable targeted, non-viral delivery of CAR constructs through advanced RNA-tLNP systems.

What You’ll Learn

mRNA & circRNA strategies in in vivo CAR-T
LNP formulation & conjugation strategies and CMC considerations
Transient expression and safety advantages

Learn About Our Services

Flyer

RNA-tLNP IND-enabling CMC

White Paper

CMC Process Challenges and Solutions forTargeted Lipid Nanoparticles(tLNPs)

White Paper

Overcoming the Manufacturing Challenges of Circular RNA

Webinar

Integrated xRNA-tLNP Platform On-demand Webinar

Targeted Lentiviral Vector (tLVV) Delivery Pathway

Leverage targeted lentiviral vectors (tLVV) for efficient and durable in vivo gene delivery.

What You’ll Learn

In Vivo CAR-T Hub

Start Your In Vivo CAR-T Journey Now!

In Vivo CAR-T Discovery

Antibody CMC for In Vivo CAR-T

Plasmid DNA for In Vivo CAR-T

RNA-tLNP Delivery Pathway

Targeted Lentiviral Vector (tLVV) DeliveryPathway

Explore OurIn Vivo CAR-T Facility

In Vivo CAR-T Discovery

Flyer

In Vivo CAR-T Discovery

Folding

Antibody Discovery for CAR-T Therapy

Webinar

Antibody Fragment CMC On-demand Webinar

Antibody CMC for In Vivo CAR-T

Poster

Faster IND Starts with Better Cell Lines

White Paper

Addressing Upstream Challenges in Antibody and Protein Production

Webinar

Antibody Fragment CMC On-demand Webinar

Plasmid DNA for In Vivo CAR-T

Flyer

Optimized Solutions for Linearized DNA

Flyer

GMP Plasmid Manufacturing

Poster

Analysis and Control of Poly(A) in mRNA Plasmid

Webinar

Development and Manufacturing Strategy for mRNA Template Plasmids

RNA-tLNP Delivery Pathway

Flyer

RNA-tLNP IND-enabling CMC

White Paper

CMC Process Challenges and Solutions forTargeted Lipid Nanoparticles(tLNPs)

White Paper

Overcoming the Manufacturing Challenges of Circular RNA

Webinar

Integrated xRNA-tLNP Platform On-demand Webinar

Targeted Lentiviral Vector (tLVV) Delivery Pathway

Flyer

Lentiviral Vector Drug Product

Flyer

Viral Vector Packaging Test

White Paper

Design of Targeting Lentiviral Vectors and Their Producer Cells

Webinar

Process Development of Lentiviral Vector On-demand Webinar

Explore Our In Vivo CAR-T Facility

Webinar

Facility Tour for In Vivo Applications

Addressing Upstream Challenges in

Antibody and Protein Production

Analysis and Control of Poly(A) in

mRNA Plasmid